News | March 18, 2009

Flexible Stenting Solutions Files IDE With FDA for FlexStent Femoropopliteal Self-Expanding Stent


March 18, 2009 - Flexible Stenting Solutions Inc. (FSS) this week submitted an investigational device exemption (IDE) application to the FDA for its FlexStent Femoropopliteal SE Stent System for the treatment of peripheral artery disease in the superficial femoral and popliteal arteries.

The company said this next generation femoropopliteal stent and delivery system may significantly improve patient care in the high growth peripheral vascular segment. While stent procedures have become widespread in the treatment of coronary arterial disease, their use in the more challenging peripheral vascular disease setting had been limited in the last several years by inadequate stents, which are prone to strut fracture in the legs. The company said its fully connected flexible FlexStent is, flexible, highly durable and fatigue resistant and has superior radial stiffness, as well as excellent conformability to and mobility with the treated vessel.

FSS’s principle investigator for the U.S. clinical trial will be Dr. William Gray, the director of endovascular intervention at New York Columbia-Presbyterian Hospital in the Center for Interventional Vascular Therapy.

“The unique design developed for the FlexStent intends to address the important issue of stent fracture in the demanding femeropopliteal arterial segment, while maintaining radial force,” said Dr. Gray. “I am looking forward to beginning the clinical trial and excited to be part of this endeavor.”

For more information: www.flexiblestent.com


Related Content

News | Peripheral Artery Disease (PAD)

June 13, 2022 — Royal Philips announced the latest results from the Tack Optimized Balloon Angioplasty (TOBA) II below ...

Home June 13, 2022
Home
News | Peripheral Artery Disease (PAD)

May 20, 2022 — New long-term data from the Safety Assessment of Femoropopliteal Endovascular Treatment With PAclitaxel ...

Home May 20, 2022
Home
News | Peripheral Artery Disease (PAD)

May 19, 2022 — One year outcomes from the Disrupt PAD III Trial comparing intravascular lithotripsy (IVL) with a drug ...

Home May 19, 2022
Home
News | Peripheral Artery Disease (PAD)

March 22, 2022 – With 60 years of experience, The Cardiovascular Care Group is nationally recognized for vascular and ...

Home March 22, 2022
Home
News | Peripheral Artery Disease (PAD)
February 21, 2022 – A research group the Department of Cardiovascular Medicine, Osaka City University Graduate School of ...
Home February 21, 2022
Home
News | Peripheral Artery Disease (PAD)
February 15, 2022 – Alkem Laboratories Limited (Alkem), an Indian multinational pharmaceutical company, has signed a ...
Home February 15, 2022
Home
News | Peripheral Artery Disease (PAD)

January 17, 2022 – The Vascular Care Group (TVCG) announced Stephen J. Hoenig M.D., successfully completed a ...

Home January 17, 2022
Home
News | Peripheral Artery Disease (PAD)

October 20, 2021 — Boston Scientific Corporation announced positive data for the Eluvia Drug-Eluting Vascular Stent ...

Home October 20, 2021
Home
News | Peripheral Artery Disease (PAD)

June 7, 2021 — A couple years ago a study showed a mortality safety signal in patients who underwent peripheral artery ...

Home June 07, 2021
Home
News | Peripheral Artery Disease (PAD)

May 17, 2021 — The anticoagulant rivaroxaban (Xarelto), in addition to low-dose aspirin, significantly reduced the ...

Home May 17, 2021
Home
Subscribe Now